News
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight Loss Pill?
Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candidate for weight management.
Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...
The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.
Investors are running into Viking Therapeutics (NASDAQ: VKTX) this week after an incident of drug-induced liver injury pushed ...
Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...
Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...
Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...
Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday ...
2don MSN
President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback